NCT05925803: An ongoing trial by AstraZeneca
This trial is ongoing. It must report results 1 year, 9 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05925803 |
|---|---|
| Title | A Multicenter, Randomized, Parallel-group, Double-blind,Two-arm Phase III Study to Evaluate the Safety and Efficacy of Anifrolumab Compared With Placebo in Male and Female Participants 18 to 70 Years of Age Inclusive With Systemic Sclerosis |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 8, 2023 |
| Completion date | Oct. 9, 2026 |
| Required reporting date | Oct. 9, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |